Genetic Markers and Outcome With Front Line Obinutuzumab Plus Either Chlorambucil or Venetoclax ‐ Updated Analysis of the Cll14 Trial
Journal article published in 2021 by
E. Tausch,
C. Schneider,
D. Yosifov,
S. Robrecht,
C. Zhang,
O. Al‐Sawaf,
B. Eichhorst,
A.‐M M. Fink,
J. Bloehdorn 
,
K.‐A A. Kreuzer,
M. Tandon,
Y. Jiang,
S. Y. Kim,
M. Porro Lura,
H. Döhner
and other authors.
,
K.‐A A. Kreuzer,
M. Tandon,
Y. Jiang,
S. Y. Kim,
M. Porro Lura,
H. Döhner
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 